Skip to main content

RT @Stiddyo: #POS0930 @XBaraliakos investigated baseline predictors differential treatment effect on ASAS20 response at

Social Author Name
Paul Studenic
Tweet Content
#POS0930 @XBaraliakos investigated baseline predictors differential treatment effect on ASAS20 response at week 12 of 473 ax-PsA using MAXIMISE trial data (#Secukinumab) -> Only nail dystrophy OR: 3 (150mg) OR: 5 (300mg) 🤔But why? #EULAR2021 @RheumNow https://t.co/srb6jGgBqe
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×